Malignancies that affect the digestive tract’s different component sites are classified as gastrointestinal cancers. Including esophageal, gastric, bile duct, liver, pancreatic and colorectal cancer.

Gastrointestinal Cancer

VJ OncologyFollow

VJ Oncology
Retweet on TwitterVJ Oncology Retweeted
myESMOESMO - Eur. Oncology@myESMO·
June 24, 2021

Just out 📣 updated ESMO Guidelines for the management of anal #cancer: latest recommendations & treatment algorithms for locoregional and advanced #analcancer
🔗http://ow.ly/RAS050FhtKb

@prof_gina_brown @Edradonc @grikamartinelli @MarianneGuren #ancsm

Reply on Twitter 1408008529194197002Retweet on Twitter 140800852919419700215Like on Twitter 140800852919419700224Twitter 1408008529194197002
VJOncologyVJ Oncology@VJOncology·
June 24, 2021

Watch @ErikaHamilton9 give a round-up of our upcoming post-#ASCO2021 Breast Cancer roundtable!

📆Wed 30-June at 6pm BST/1pm EDT/10am PDT 📆

Join Erika, @curijoey, @stolaney1 & Andrew Tutt as they cover the latest key breast cancer data!

Register now 👉https://bit.ly/3wTS07P

Reply on Twitter 1408115806551019521Retweet on Twitter 14081158065510195216Like on Twitter 140811580655101952112Twitter 1408115806551019521
VJOncologyVJ Oncology@VJOncology·
June 24, 2021

⏰⏰⏰ 5 MINS ⏰⏰ ⏰

We're about to get started with the post-ASCO GU Cancer Session!

It's not too late to join the discussion & learn from this amazing panel of leading experts!

👉http://tinyurl.com/GU-Cancer 👈

#ASCO2021 @ASCO @OncoAlert #UroOnc #BlcSM #kcsm #VJSessions

Reply on Twitter 1408106393643720720Retweet on Twitter 1408106393643720720Like on Twitter 14081063936437207201Twitter 1408106393643720720
VJOncologyVJ Oncology@VJOncology·
June 24, 2021

VIDEO: The IMMULAB trial: pembrolizumab with local ablation for patients with early-stage HCC w/ Arndt Vogel of the Hannover Medical School

Watch now 👉http://ow.ly/381S50Ff8ME👈

@VJOncology @OncoAlert @ASCO #ASCO21 #HPBCsm #LiverCancer #Oncology #OncoAlert

Reply on Twitter 1408096396721463301Retweet on Twitter 1408096396721463301Like on Twitter 14080963967214633012Twitter 1408096396721463301
VJOncologyVJ Oncology@VJOncology·
June 24, 2021

🚨 1 hour warning! 🚨

Learn about adjuvant pembro, CLEAR & KN-426 in RCC, immunotherapy & enfortumab vedotin in bladder cancer and much more!

DON'T MISS OUT! REGISTER NOW!
http://tinyurl.com/GU-Cancer

Reply on Twitter 1408092563479973891Retweet on Twitter 1408092563479973891Like on Twitter 1408092563479973891Twitter 1408092563479973891
Load More

Gastrointestinal Cancer

Malignancies that affect the digestive tract’s different component sites are classified as gastrointestinal cancers. Including esophageal, gastric, bile duct, liver, pancreatic and colorectal cancer.

View all videos

VJ OncologyFollow

VJ Oncology
Retweet on TwitterVJ Oncology Retweeted
myESMOESMO - Eur. Oncology@myESMO·
June 24, 2021

Just out 📣 updated ESMO Guidelines for the management of anal #cancer: latest recommendations & treatment algorithms for locoregional and advanced #analcancer
🔗http://ow.ly/RAS050FhtKb

@prof_gina_brown @Edradonc @grikamartinelli @MarianneGuren #ancsm

Reply on Twitter 1408008529194197002Retweet on Twitter 140800852919419700215Like on Twitter 140800852919419700224Twitter 1408008529194197002
VJOncologyVJ Oncology@VJOncology·
June 24, 2021

Watch @ErikaHamilton9 give a round-up of our upcoming post-#ASCO2021 Breast Cancer roundtable!

📆Wed 30-June at 6pm BST/1pm EDT/10am PDT 📆

Join Erika, @curijoey, @stolaney1 & Andrew Tutt as they cover the latest key breast cancer data!

Register now 👉https://bit.ly/3wTS07P

Reply on Twitter 1408115806551019521Retweet on Twitter 14081158065510195216Like on Twitter 140811580655101952112Twitter 1408115806551019521
VJOncologyVJ Oncology@VJOncology·
June 24, 2021

⏰⏰⏰ 5 MINS ⏰⏰ ⏰

We're about to get started with the post-ASCO GU Cancer Session!

It's not too late to join the discussion & learn from this amazing panel of leading experts!

👉http://tinyurl.com/GU-Cancer 👈

#ASCO2021 @ASCO @OncoAlert #UroOnc #BlcSM #kcsm #VJSessions

Reply on Twitter 1408106393643720720Retweet on Twitter 1408106393643720720Like on Twitter 14081063936437207201Twitter 1408106393643720720
VJOncologyVJ Oncology@VJOncology·
June 24, 2021

VIDEO: The IMMULAB trial: pembrolizumab with local ablation for patients with early-stage HCC w/ Arndt Vogel of the Hannover Medical School

Watch now 👉http://ow.ly/381S50Ff8ME👈

@VJOncology @OncoAlert @ASCO #ASCO21 #HPBCsm #LiverCancer #Oncology #OncoAlert

Reply on Twitter 1408096396721463301Retweet on Twitter 1408096396721463301Like on Twitter 14080963967214633012Twitter 1408096396721463301
VJOncologyVJ Oncology@VJOncology·
June 24, 2021

🚨 1 hour warning! 🚨

Learn about adjuvant pembro, CLEAR & KN-426 in RCC, immunotherapy & enfortumab vedotin in bladder cancer and much more!

DON'T MISS OUT! REGISTER NOW!
http://tinyurl.com/GU-Cancer

Reply on Twitter 1408092563479973891Retweet on Twitter 1408092563479973891Like on Twitter 1408092563479973891Twitter 1408092563479973891
Load More
Latest videos VJSessions Subtypes Topics Conferences Features Editorial Board

Subtypes

Gastric Cancer
Colorectal Cancer
Liver Cancer
Bile Duct Cancer
Pancreatic Cancer
2:36
Real-world use of nivolumab in gastric cancer
Yu Sunakawa • 8 Jun 2021
7:21
Neo-AEGIS: preliminary results of the Phase III RCT of CROSS versus perioperative chemotherapy
John V. Reynolds • 27 May 2021
6:54
CheckMate 649: 1L nivo + chemotherapy improves OS
Mohamed E. Salem • 9 Jun 2021
3:07
Advances in esophageal cancer and unanswered questions
John V. Reynolds • 27 May 2021
View All Videos
2:45
1L FOLFOXIRI plus cetuximab or bevacizumab for RAS wild-type mCRC
Yu Sunakawa • 8 Jun 2021
11:32
Final results from DESTINY-CRC01: T-Dxd in HER2-expressing mCRC
Mohamed E. Salem • 9 Jun 2021
4:25
FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab in mCRC
Sebastian Stintzing • 19 May 2021
2:59
Clinical implications of HER2 in GI cancers
Daniel Catenacci • 19 May 2021
View All Videos
4:07
80mg regorafenib plus pembrolizumab for 1L HCC
Richard D. Kim • 10 Jun 2021
1:25
The IMMULAB trial: pembrolizumab with local ablation for patients with early-stage HCC
Arndt Vogel • 11 Jun 2021
1:43
Liquid biopsy biomarkers for early detection and treatment prediction in HCC
Augusto Villanueva • 19 May 2021
0:40
Elevated alpha-fetoprotein in aHCC patients and increased responsiveness to ramucirumab
Augusto Villanueva • 19 May 2021
View All Videos
2:41
Liposomal irinotecan plus 5-FU & leucovorin for patients with metastatic BTC
Richard D. Kim • 10 Jun 2021
4:03
Phase I/II trial of zenocutuzumab for tumors with NRG1 fusions
Alison M. Schram • 4 Jun 2021
2:40
FIGHT-202: pemigatinib for FGFR2 altered CCA
Arndt Vogel • 11 Jun 2021
2:42
Final results from ClarIDHy: ivosidenib in IDH1-mutated CCA
Ghassan K. Abou-Alfa • 2 Jun 2021
View All Videos
4:03
Phase I/II trial of zenocutuzumab for tumors with NRG1 fusions
Alison M. Schram • 4 Jun 2021
9:02
Preoperative CRT improves overall survival in pancreatic cancer: long-term results of PREOPANC
Casper H. Van Eijck • 17 May 2021
5:17
Mutant p53 and oncogenic KRAS drive metastasis in pancreatic cancer
Michael Kim • 8 Apr 2021
1:10
Future targets for pancreatic cancer treatment
Michael Kim • 8 Apr 2021
View All Videos

Topics

Immuno-Oncology
CAR-T & Cellular Therapy
Trial Updates
Molecular Profiling
Radiotherapy
4:07
80mg regorafenib plus pembrolizumab for 1L HCC
Richard D. Kim • 10 Jun 2021
2:36
Real-world use of nivolumab in gastric cancer
Yu Sunakawa • 8 Jun 2021
2:14
Immunotherapy of NETs
Jonathan Strosberg • 7 Jun 2021
11:32
Final results from DESTINY-CRC01: T-Dxd in HER2-expressing mCRC
Mohamed E. Salem • 9 Jun 2021
View All Videos
1:13
Bi-specific antibodies in HER2+ gastric cancer
Hyun C. Chung • 13 Jan 2021
2:26
alloSHRINK: Phase I first-in-human study evaluating CYAD-101, an allogeneic CAR-T in mCRC
Hans Prenen • 22 Jan 2021
View All Videos
4:07
80mg regorafenib plus pembrolizumab for 1L HCC
Richard D. Kim • 10 Jun 2021
2:41
Liposomal irinotecan plus 5-FU & leucovorin for patients with metastatic BTC
Richard D. Kim • 10 Jun 2021
2:36
Real-world use of nivolumab in gastric cancer
Yu Sunakawa • 8 Jun 2021
2:45
1L FOLFOXIRI plus cetuximab or bevacizumab for RAS wild-type mCRC
Yu Sunakawa • 8 Jun 2021
View All Videos
2:40
FIGHT-202: pemigatinib for FGFR2 altered CCA
Arndt Vogel • 11 Jun 2021
1:26
Personalized medicine in NETs
Peter M. Anderson • 25 May 2021
2:59
Clinical implications of HER2 in GI cancers
Daniel Catenacci • 19 May 2021
5:26
FIGHT update: 1L bemarituzumab in FGFR2b+ gastric cancer
Daniel Catenacci • 19 May 2021
View All Videos
7:21
Neo-AEGIS: preliminary results of the Phase III RCT of CROSS versus perioperative chemotherapy
John V. Reynolds • 27 May 2021
4:25
Final OS from NETTER-1: lutetium-177-DOTATATE in patients with midgut NETs
Enrique Grande • 4 Jun 2021
2:08
FDG-PET avidity as a prognostic biomarker in RCC
Viktor Grünwald • 7 Jun 2021
9:02
Preoperative CRT improves overall survival in pancreatic cancer: long-term results of PREOPANC
Casper H. Van Eijck • 17 May 2021
View All Videos

Conferences

AACR 2021
ASCO GI 2021
ESMO WCGIC 2020
ESMO 2020
ASCO 2020
3:05
IMbrave150: updated data on atezo plus bev versus sorafenib in HCC
Peter R. Galle • 20 Apr 2021
2:25
Using oncolytic viruses in solid tumors
Kaidre Bendjama • 15 Apr 2021
4:35
TG6002, an oncolytic virus induces expression of a pro-drug activating enzyme in advanced GI cancers
Kaidre Bendjama • 15 Apr 2021
11:49
Racial differences in somatic mutations among patients with early-onset CRC
Andreana N. Holowatyj • 9 Apr 2021
View All Videos
2:21
Updates in the use of neratinib in fibrolamellar carcinoma and biliary tract cancer
Ghassan Abou-Alfa • 21 Jan 2021
3:05
Alliance A021501: preoperative mFOLFIRINOX +/- hypofractionated RT for pancreatic cancer
Joshua E. Meyer • 20 Jan 2021
3:29
POLO: maintenance olaparib in BRCA1/2 metastatic pancreatic cancer
Mohamed E. Salem • 20 Jan 2021
1:32
ASCO GI: updates in CCA, ALLIANCE & FGFR inhibition
Namrata Vijayvergia • 20 Jan 2021
View All Videos
1:28
Future approaches in esophageal cancer
Omkara Veeranki • 1 Jul 2020
6:21
Patient-derived orthotopic xenograft models of esophageal adenocarcinoma
Omkara Veeranki • 1 Jul 2020
2:10
Impact of COVID-19 on esophageal cancer treatment
Omkara Veeranki • 1 Jul 2020
3:31
Correlation between CEA and TNM stage in CRC
Venkata Pradeep Babu • 10 Jul 2020
View All Videos
4:19
Impact of sexual dimorphism in cancer healthcare
Anna D. Wagner • 16 Oct 2020
3:11
PRS-343 in HER2-Positive Solid Tumors: A trial update
Geoffrey Ku • 24 Sep 2020
4:01
The role of immunotherapy in gastrointestinal cancers: an update from ESMO
Geoffrey Ku • 24 Sep 2020
7:06
Impact of biological sex on incidence, pathology and treatment responses to cancer
Anna D. Wagner • 23 Sep 2020
View All Videos
3:09
Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults
Daneng Li • 4 Jul 2020
10:08
Evolving role of HER2 targeted therapies in gastroesophageal cancers
Barbara Burtness • 28 May 2020
10:27
Adjuvant treatment of colon cancer: three vs six months of FOLFOX/CAPOX
Alberto F. Sobrero • 18 May 2020
3:24
COVID-19 & the management of cancer patients
Alberto F. Sobrero
View All Videos
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals